Fasting and meal‐stimulated serum C‐peptide in long‐standing type 1 diabetes mellitus
Authors' conclusion
Stimulated C-peptide was detectable in an additional 10% of individuals compared with fasting in individuals with >5 years of diabetes duration. T90 and T120 MMTT measurements showed good concordance with the MMTT total AUC. Overall, there was a decrease of C-peptide at 1-year follow-up.
Study context
- Population
- Individuals with T1D and diabetes duration >5 yearsMixed-meal tolerance test (MMTT) n = 168
- Participants
- 607 individuals
- Outcome
- Detectable fasting serum C-peptide (≥ 3.8 pmol/L)
Methodological details1-year follow-up, MMTT subpopulation
- 1-year follow-up
- MMTT subpopulation
Main finding
As reported in the abstract
Participants with detectable fasting serum C-peptide
153
25%
Fasting C-peptide significantly lower at Year 1 vs Year 0 (n = 535); p < 0.001
effect size = −0.16
Observational data: associations, not effects.
Further findings
Clinical determinants of residual C-peptide
- Higher fasting C-peptide associated with higher age at diagnosis, shorter disease duration and less frequent insulin pump use
MMTT C-peptide
- Non-detectable fasting and post-meal C-peptide
- 109 of 168 (65%)
- C-peptide detectable only at MMTT, not fasting
- 17 (10%)
- T90 and T120 C-peptide values concordant with total AUC
Original publication
Fasting and meal‐stimulated serum C‐peptide in long‐standing type 1 diabetes mellitus. Diabet Med. Published 4 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →